The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer
Quick Facts
- Publication title: The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer
- Journal: J CANCER RES CLIN
- Year: 2022
- DOI: 10.1007/s00432-022-04071-5
- PMID/PMCID: 35672525; PMC11800937
Research overview
The ALTER 0303 trial was a multicenter, double-blind, phase 3 randomized clinical study to evaluate the efficacy of anlotinib in patients with advanced non-small cell lung cancer (NSCLC). Our results demonstrate the potential of plasma exosomal lnc-SNAPC5-3:4 as a biomarker for monitoring anlotinib efficacy.
Key findings
In the plasma exosomal RNA profiles of the 5 patients with advanced NSCLC during treatment with anlotinib, 7 miRNAs, 3 lncRNAs, and 83 mRNAs were significantly dysregulated.
The regulation trend was opposite when the treatment was effective and ineffective, showing dynamic changes.
Thus, it can be used as a potential biomarker for monitoring the efficacy of anlotinib.
Study design
We enrolled 5 patients with advanced NSCLC, and 15 blood samples were collected before anlotinib treatment, when the treatment was effective, and when the treatment was ineffective.
The plasma exosomal RNA profiles were analyzed by whole-transcriptome sequencing at three different stages.
The expression of dysregulated exosomal RNAs in 43 additional patients was also verified by real-time quantitative PCR.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: EV Isolation & Purification, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2022. DOI: 10.1007/s00432-022-04071-5. PMID/PMCID: 35672525; PMC11800937.